Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PFIZER LIMITED ( (IN:PFIZER) ) just unveiled an update.
Pfizer Limited has clarified a technical issue related to its XBRL submission of unaudited financial results for the quarter and half year ended 30 September 2025. The company said its board approved the results on 12 November 2025 and filings were made in both PDF and XBRL formats within the prescribed timelines.
According to the clarification, an incorrect selection of ‘Reporting Type’ and ‘Reporting Quarter’ occurred in the initial XBRL filing. After receiving guidance from the National Stock Exchange on 28 November 2025, Pfizer resubmitted a revised integrated financial filing in XBRL, which now correctly reflects both quarterly and half-yearly results on the exchange’s website.
More about PFIZER LIMITED
Pfizer Limited is an Indian pharmaceutical company engaged in the manufacturing and marketing of prescription medicines and healthcare products. The company operates in highly regulated markets and is listed on Indian stock exchanges, where it complies with disclosure and financial reporting norms under SEBI regulations.
Average Trading Volume: 2,850
Technical Sentiment Signal: Hold
Current Market Cap: 222.6B INR
See more insights into PFIZER stock on TipRanks’ Stock Analysis page.